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The activation of signal transduction pathways by 
m utation or overexpression of cellular oncogenes has 
been associated with neoplastic transformation. In 
this study, we addressed the therapeutic potential of 
ribozymes targeted against the activated H-ras onco-
gene as well as against the nuclear proto-oncogenes 
c-fos and c-myc in the FEM human melanoma cell line 
containing a H-l'as mutation. FEM cells transfected 
w ith the anti-ras ribozyme were shown to have the 
longest doubling time, the least DNA synthesis, and 
the fewest colonies in soft agar when compared with 
R ecent advances in can cer biology have demon-strated that tumorigenesis occurs as a result of genetic alterations in many types of cancers [1,2]. ]n cutaneous J11 a l~gnan ci es, vari o us in v.estig~to. rs have suggested a hnkage be tween ultraVIOlet Irra-
dia tion-induced mutations in oncogenes (e .g., ras) and tumor 
progression [3,4]. Initial reports indicated that ras mutations were 
detected in 24% of cultured m elano m a cell lines [5] . More recent 
studies have shown muta tions in 36':10 of tumor material from 
melanoma patients, with an increase to 45% in melanom as beyond 
Clark's level II [6]. In addition, ;11 11;(1'0 transformation studies using 
oncogenes induced a m elanoma-like phenotype in cul tured m ela-
nocytes [7]. Specifically, m elanocytes transformed with the acti-
vated H-ras gene exhibit the malignant phenotype and possess the 
cytogenetic aberrations observed in primary melanomas [8]. T he 
biological importance of these ·genes has made them attractive 
targets fo r m anipulation of gene expression . R ecently, many trials 
have been undertaken to study this concept by using gene modu-
lators such as anti-sense o ligodeo:\.'Ynucleotides o r catalytic RN As 
(ribozymes) [9,10]. With the proven therapeutic potential of 
gene-modulating agents in experimental m odels, trials are being 
ini tiated to test the clinical application of this approach. 
Hammerhead ribozymes, as used in tlus study, can promote the 
site-specific cleavage reaction of the targe t RNA in a truly catalytic 
manner [11,12] . For instance, a hammerhead Iibozym e designed to 
target activated H-rl1s mRNA was shown to cleave only tile mutated 
transcripts and leave its normal counterpart unaff'ected ;11 lI;fro [13 ]. 
T his anti-ras ribozyme was shown to have greater efficacy in inhibiting 
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transfectants with ribozymes against c-fos or C-IIIJ'C 
mRNA. Furthermore, anti-ras ribozyme clones showed 
a dendritic appearance in monolayer culture that was 
associated with enhanced melanin synthesis. These re-
sults suggest that the anti-I'as ribozyme could affect not 
only the proliferation but also the differentiation pro-
cess of human melanoma cells ill Vitl'O. They also rein-
force the role of anti-oncogene ribozymes as suppres-
sors of the neoplastic phenotype of melanoma cells. Key 
word: H-ras. ] Illvest D erlllatol 106:275-280, 1996 
H-ras gene expression and reversing tile transfomled phenotype than 
a mutant I;bozyme mainly capable of anti-sense activity [1 4,15]. 
Ribozymes have been previously examined as an ti-oncogene, anti-
HIV, and anti-drug resistance agents [14 -20]. 
R ecent progress in cell biology has de fin ed ras-regulated signal 
transduction from the plasma m embrane to the nucle us. M utated 
raj' oncogene- encoded proteins are presllmed to activate the 
nucl ear proto-oncogen es that lay downstream from them, resulting 
in a tra nsformed phenotypic alteration [21]. In this study, we have 
attempted to compare the ;11 Il i/I'O th erape utic potential ofribozymes 
design ed to cleave activated H-ras and the nuclear proto-oncogenes 
c-Jos and C-III )'C in human m elanoma cells possessing a H - ras 
mutation. W e used the glucocorticoid-inducible murine mammary 
tLUnOr virus promoter to demonstrate the reversible effect of I;bozymes 
against oncogenes on the suppression of the melanoma phenotype. 
MATERIALS AND METHODS 
Cells Human m elanoma FEM cells were obtained fi'om Dr. Oystein 
Fodstad (Os lo, Norway) and their characteristics ha ve been previously 
described [22.23 ]. The FEM ce ll line has a H- rns codon 12 mutation, in 
w hich the nomlally glycine- encoding GGC sequence is converted to GUC, 
encoding va line [1 7]. Cell s were grown in monolayers in I~PM I 1640 
medium supplemented with 10%, fe tal bovine serum . Three days afte r 
seeding, they were treated with 0 .5 J.l.M dexamethasone (Dex: Sigma 
C hemical Co., St. Louis, MO) for 48 h w hen desired . Th)~nidine uptake 
was used to determine the rate of ['H]dThd incorporation into tri chloro-
acetic acid-precipitable m aterial [1 6]. Colony formation in soft aga r was 
perfo rmed as previously described [24]. Briefly, the top layer co nsisted of 
5 X 10' viable ce ll s suspended in 0.3% agarose. RPMl 1640, and serum at 
concentrations of ·1, 10. or 20%, w ith or witho ut 0.5 J..I.M Dex, overlaid on 
a 1')1, agarose layer in a 35-111111 culture plate. To assess clonjng efficiencies 
in the presence of Dc". cell s were first grown for 24 h in culture m edium 
containing 0.5 J..I.M Dex and were then plated under dlC conditions 
described above . Colo nies wcre counred under a light microscope 10 -1 4 d 
aftcr seeding. 
Relative Melanin Content of C e lls Cell s were seeded to achieve a 
density of approximate ly 5 X 105 cells/100mm plate after 4 d in culture. 
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After attachment, cells we re treated with 0.5 /LM Oex whcn desired, From 
each plate,S X 106 cells were collected by trypsinization and subjected to 
a 2000S ccntrifugation. Cel l pellets were di ssolved in 1 ml of 1 N KOH at 
SO°C for 1 h. This hydro lysate was centrifugcd at 12000"~ fori 0 min. Thc 
relative I11cianin concentrations of th e supe rnatants were d etcnnincd by 
measuring the 0.0. at 492 nm [25]. A standard curvc was prepared by 
dissolving known amounts of synthetic melanin (S igma) in KOH. The 
resu lts arc expressed as: Melanin synthesis (,X,) = amoun t (p.g) of experi-
mental ce lls/amount (/Lg) of control cell s X I 00. 
RNA Sequences of Substrates and Ribozymes T he seq uence of 
RNA tra nscript of activated H-ms, c-jC)S, and c- ))I)'c targe ted by the 
ribozymes is cncoded by the fo llowing nucleotides (nt): Target activated 
H - rns mRNA (exon 1, 1697-1712nt): 5'-GGC GGC GUC* GGU GUG 
G-3' (Bold letter and asterisk denote the recognition sequence and site of 
cleavage reaction, respectively). The rnsRz: 5' -CCAC ACC CUG AUG 
AGU CCG UGA GGA CGA AAC GGC GCC-3' . Target c-fos mKNA 
,(exon 1, 914-938nt): 5'-A CUA CGA GGC GUC* AUC CUC CCG 
CUG-3'. T he fosRz: 5'-CAG CGG GAG GAU CUG AUG AGU CCG 
UGA GGA CGA AAC GCC UCG UAG U-3 '. Target c- ))I)'c RNA (exon 2, 
1224-1 246nt): 5' -C AUC CUG UCC GUC* CAA GCA GAG G-3 '. The 
1I/)'cRz: 5'-C CUC UGC UUG CUG AUG AGU CCG UGA GGA CGA 
AAC GGA CAG GAU G-3'. Each hammerhead ribozyme was constructed 
with the samc stem loop region and distinct Aanking sequences comple-
mentary to the substrate RNA essentia lly as desc ribed by Haseloff and 
Gerlach (26]. The ribozymes werc tested for ill "ilro cleavage of their ta rget 
I\NAs for H-rns [1 6]; for C-jClS [1 9]; unpublished results for C-IIlj'C. 
Plasmid Construction The fosRz used in this study was cloned into the 
plasmid pMAMneo (Cion tech) as previously described [1 9]. Ribozymes 
against activated H-ros or c-))I )'c were subcloned in to pMAMneo using two 
s)'ntheti c single- stranded oljgonucleotides designed to contain sequences for 
creating two restriction sites (Nhe I and Sal I) fo llowing a previously 
reported method [1 9]. The plasmid pMAMneo contains the murine mam-
Ill:l t:y tun10r virus dcxanlcthasone-induciblc pr0J11ote r to regulate expres-
sion of ribozyme RNA transcripts. T he seq uence and orientation of the 
inserts wcre confirmed by dideo,,:ynucleotidc sequcncing of the construct 
ribozymc using thc Sequcnase kit (U.S. J3iochemical Corp.). 
Transfeetioll by Electroporatioll SubconAuently growing cell s were 
tr;lI1sfected by cicctroporation according to a previous ly published method 
[16] . T he ce lls were then se lected in growth mediunl containing 500 f.Lg/ ml 
genetic in (G4IS; Gibeo, Gaithersburg, MO) for 3-6 wk. Individua l G418-
resistant co lonies were picked, grown, and screened for expression of the 
ribozymc by reverse transcriptase-polymerase chain reaction (RT -PCH .. ). 
Polymerase Chain Reaction R T -PCR, following tha t of a commer-
cially ava ilable protocol (GencAmp, Perkin-Elmer-Cetus), was used to 
detect ribozyme, basic fibroblast growth factor (bFGF), and phosphoglyc-
er:ltc kinase (PGK) expression. and was pcrfornlcd as prev iously d escribed 
[1 9,27J. 
Northern Analysis Total J\NA and poly(A) mRNA were prepared by 
the guanid ium isothiocyanate method [19]. RNA was size-fractionated and 
transferred to a nylon membrane (Hybond-N; Amersham , Arlington 
Heights, IL). Hybridizations were carried out with probes "adiolabeled by 
the random primer method as described [28]. 
RESULTS 
FEM Cells in Culture FEM human melanoma cells were trans-
fected with pMAMneo containing ribozymes against activated 
c-H-ras (l'IlsRz), c-fos (fosRz) , and C-III}'C (lIIJ'cRz) oncogenes by 
e lectroporatio n. These transfectants were trea ted with G4 18 for 
3-6 wk, and 8-16 G418-resistant colonies were selected. For 
screenin g, R T -PCR was p erformed to demonstrate the presence of 
ribozyme transc ripts in the transfectants. T h e RN A transcripts of 
rasRz, fosRz, and /}/J'cRz were actively expressed in the diiferent 
clones (Figs 1, 2, lnll es 3-6) . In contrast, no ribozyme expression 
was detected in FEM contro l cell s transfected with pMAMneo 
lackin g the ribozym e seq uences (Figs 1, 2, Ielll es 1,2) . Ribozyme 
expression was induced approximate ly 1 .5- to 5-fold by Dex 
administration (Figs 1, 2 , Inlles 4,6) compared with tha t of un-
treated cell s (/nJ/es 3,5). The FEM ribozyme transfectants without 
Dex treatment also exhibited a detectable le vel of ribozyme 
expression. This baseline expressio n might be linked to th e leakage 
induced by 10% serum in the culture medium [29]. To evaluate the 
etficacy of accelerated ribozyme expression, t ran sfectants were 
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Figure 1. Gene expression ofFEMl'lIsRz transfectants. LOllrs I and 2. 
FEMpMAMnco vector only clone; 101l('s 3 and 4, FEMrosRz clone 1 
(Ras- 'I) , Imll's 5 and 6, FEMrosRz clone 6 (Ras-6). To tall\NA W:1S prepared 
from log-phase cells grown in either the absence (- ) or prcsence (+ ) 0[0.5 
f.LM dexamethasone (De.>:) fo r 48 h. PGK, phosphoglycerate kinase; Kb, 
kilobases; blJ, base pairs. Gene expression has been normalized (18) to FEM 
ce lls (vector on ly) . H-ros ("1.0, 0.8 , 0.95 , 0.3, 0.25, and 0.05); c-fos (1.0. 
0.35. '1.2, 0.3, 0.1, and 0.1 5); C-jllll (1 .0, 1.0, 0.85, 1.0,0.6, and 0.65); C-/II)'c 
(1 .0,1.2,0.05,0.05,0.04, and 0 .02); PGK (1.0,1.0, 1.25,1.1 , 1.2, and 1.2); 
bFGF ( 1.0, 0.95, 0.8, O.B, 0.35, and 0 .3); PGK (1.0. 1.2, 0.8, 0.95, 0.95, aod 
0.S5). 
transiently exposed to 0.5 /LM Dex for 48 h . At t hjs con centration 
of De x, n o sig nifi cant alterations were observed in parent FEM cell 
(data not shown) and control FEM cell s transfectcd with pMAM-
n co only (Table I, Fig 3) on cell growth , morpholof,'Y, and 
melanin synthesis. 
Gene Expression in FEM Cells To determine whether these 
r ibozymes cou ld affect expression of th e substrate RNA, we 
examined the mRNA levels of each target gene by Northern 
analysis. In rnsRz clones Ras-l and Ras- 6, the expression of H-ras 
mRNA was decreased compared with con tro l cells. Moreover, 
clone Ras-6, with a relative ly larger amollnt of ribozyme expres-
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Figure 2. Expression of ribozymes and ta.rget transcripts in FEM-
JosR:z. and "'}'cR.Z clones. The .li)s ribozyme was expressed ill FEM cell s 
(A) and fos gene expression was characterizcd and compared to phospho-
glycerate kinase (PGT<) genc expression. Lalles J and 2. FEMpMAMnco 
vector only clone; fall cs J and 4. FEMji,sR.z clone 3 (Fos-3); falll's 5 and 6, 
clone 4 (Fos- 4). Cene expression has been normalized (18) to FEM cells 
(vector only). c-fos (1.0 , 0.35, 0.2, 0 .01, 0.4, and 0 .01); PCI( (1.0, 1.0, 1.0, 
1.1, 1.2, and 0.9) . The C-III)IC ribozyme was expressed in FEM ce ll s (B) and 
the C-)//)'c gene expression was characterized and compared with PCK gene 
expression . Lalles J and 4. FEM)//)'cRz clone 3 (Myc-3); falles 5 and 6; clone 
10 (Myc-10). C-)// )'c (1.0, 0.85, 0.8, 0.7 , 0.6, and 0.2) ; PCI( (1.0 , 1.2, '\.3, 
1.15, 1.2, and 1.3). Each transfectant w;] s treated with Dex (0.5 f1.M) for 48 
h , when desired. 
sion than clone Ras-1 , exhibited correspondingly less H-I'lIS mRNA 
(Fig 1). Thus, the re appeared to be an inverse correl ation between 
the level of ribozyme and target mRNA expression. T ransfectants 
containing the ji)sRz (clones Fos-3 and -4) and the lII),cR z (clones 
Myc-3 and -10) al so demon strated a similar inverse correlation (Fig 
2). 
The effects of ,;bozym e action on cell growth and DNA synthesis 
were inves tigated (Table I). The doubling tim e was 2.3 to 2.9 
tim es longer in Dex-treated rasRz-expressing FEM cells than in th e 
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control Dex-treated clone, ranging from 47.7 to 58.6 h (Ras-l and 
R as- 6, respective ly). Clone Ras-6, w ith a greater amount of 
ribozyme expression and lesser amount o f target I'lIS mRNA, had a 
longer doubling time than clone R as-1. Tnlll sfectants expressing 
j()sR z and III),cR z also had in creased doubling times, though to a 
lesser extent than msRz clones. In the JosRz clones, 1.9- and 
1.7-fold longer do ubling times were shown in Fos-3 and Fos-4 
cells, respectively. Myc-3 and Myc-lO cells demonstrated 1.5- and 
1.7-fold longer doubling times compared to control cell s. The 
in creased doubling time in ribozym e-expressing transfectants was 
associated with diminjshed DNA synthesis as exhibited by eH]thy-
nudine incorporation into DNA (Table I) . In two selected clones 
with each ribozyme, th e abjlity of the ,;bozyme to reduce target 
mRNA expression correlated with prolonged doubling time and 
decreased DNA synthesis. Colony form ation in soft agar, an 
indication of anchorage-independent g rowth w as decreased in 
ribozym e-treated cells , w ith the greatest growth inhibition evident 
in R as-6 cell s (Table I). 
In order to guard against clonal vari ation following the transfec-
tion and selectio n process, the ribozyme-containing transformants 
from four clones were pooled and analyzed for ill 1Iitro growth 
characte ristics. The pooled msR z expressing cells continu ed to 
exhibit more sluggish ill vitro cell growth followed by the pooled 
josRz and IIIJ'cR z clones (Table I). 
FEM Cellular Morphology MOI-phologically, control FEM 
cells transfected with pMAMneo were spindlc or triangle shaped 
(Fig 3A) similar to parent FEM cells (data not shown). This contro l 
clone was unaffected by Dex treatment. In contrast, ribozym e 
transfectants showed an altered m o rphology (Fig 3B), even in the 
absencc of . Dex (data not shown) . Dex-treated rasRz clones 
revealed a more dendriti c shape compared with the control cells 
(Fig 3B). T he josKz induced a significant bipolarity in shape (Fig 
3Q. M ycR z clones had a more Aattened , som ewhat reticulated 
appearance (Fig 3D) . These clones morpho logically reverted to 
control FEM cells without Dex treatment within 2-3 wk (data not 
shown) . R elative m elanin content was also in creased in the trans-
fectants (Table I) : 2 .62 and 3.53 times (Ras-l and -6, resp ectively); 
1.82 and 2. 15 times (Fos-3 and -4, respectively); and 2.30 and 2.61 
times (Myc-3 and -10 , respectively). The sam e pattei'll of in creased 
melanin expression was observed when the pooled clones were 
analyzed (Table I) . Thus, among these anti-oncogene ribozymes, 
msKz clones dcmonstrated the longest doubling time, the least 
DNA synthcsis, and the lowest efficiency of soft 'lgar colony 
form ation. Mo reover, the msRz stimulated m elanin synthesis m ost 
effectively. 
In te rms of gene expression , dccreases in activa ted H-ms exp res-
sion were associated with dow nreguJation of c-jos expression (Fig 
1). However, the expression of C-jllll , encoding the otber compo-
ncn t of the AP-l complex, was not altercd in t:ansfectants. T he 
expression of C-IIIJ'C was decreased in ribozym e clones of FEM ce lls. 
Usin g RT-PC R , the expression of bFGF was depressed in thc FEM 
msR.z clonc, Ras- 6, w hereas con trol PGK expression was not 
altered. 
DISCUSSION 
T he activa tion o r mutation of cellular oncogenes plays a crucia l role 
in tumor bio logy [21] . Mutations in ras genes have been found in 
approximately 15'1., of solid tumors [30] . A recent rcport has 
suggested that /'as mutations were detected in 36% of p,;mary 
m elanomas [6] . Inte resting ly, while /'as mutations w ere not found in 
level r m clanomas, m ost of the mutations occured in l'nelanom3s 
beyond level IT, indicating that ras mutations ma y play an important 
ro le in m elan om a progression. 
This is supported by our results demonstrating that Dex-treated 
rasRz transfectants (Ras-6) represented longer doubling times, 
lower thymidine in corpo ratio n rate, and fewer number of colonies 
in so ft agar, compared with those observed in IosR z o r l/IJ'cRz 
clones . T he levels of disrupted target mRNA wcre not exactly the 
sa m e in a1.l ribozYl11 e clones; however, our results indicate that 
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Table I. Growth Char acterist ics and M elanin Synthesis of Ribozyme-Transfected FEM Human Melanoma Cells 
Doubling ['HjT hymidinc Colonies in Soft Agar Melani n Contcnts t 
Cell Lines" Dcx" T ime (h) Uptake' (%) Serum: 1 ')\./20%'/ ('Yc.) 
FEMpMAMneo 
20.3 100 198/576 100 
+ 20.4 96.6 162/500 118 
FEMrnsRz 
Clone 1 35.2 30.4 0/56 156 
+ 47 .7 21.3 0/3 1 262 
Clone (, 32.2 31.9 0/48 153 
+ 58.6 '18 .2 0/15 353 
Pooled clones + 60.1 23.5 1/20 311 
FEMJosR.z 
Clone 3 31.4 47.0 18/.1 12 185 
+ 39.2 37.0 1/28 2 15 
Clone 4 30.9 54.0 27/ 134 160 
+ 35 .5 51.0 3/40 182 
Pooled clones + 38.5 39 .0 3/35 245 
FEM III )'cR.z 
CloDe 3 26 .8 77.6 311188 139 
+ 30.8 33 .1 11 /52 230 
Clone 10 27.5 57.0 22/ 155 242 
+ 35.2 32.4 4/48 261 
Pooled clones + 33.1 38.0 8/5 1 222 
" FEMpMAMnco. FEM ce lls transfc ctcd with pM AM nco vcc[Or onl y; FEM rns R z. FElV\fi'sR..z. and FEMIII),dtz. FEM cells tTa nsfccrcd with a ribozym c [;l rgctcd against activated 
H-rns, c.:-Jos. and C-III )'C, respectively. 
" Dexa methasone (Dcx) was used .n a cOllcelltration of 0.5 MM. 
r To determin e the rate of[JH]thymidhlc upt41kc in acid-so luhle IIlOl tcr ia l. cells were grow ll for 48 h in med ium w ith or wi th out Dcx. all d were pulsed fo r 1 h with r-'H]chymidine. 
washed. , cid-precipit,ted, , nd coun ted. The FEM pM AMneo (-Dcx) (100%) represented 3.29 fl11 uJ/ mgD NA/ h. These resul ts represent the mean of three separate experiments. 
T here was less chan 10'X, variation in the data points . 
• f Five thousand viable cell s were grown in 0.3% agar w ith I or 20'X. fetal bovinc scrum . T hirteen dHYS "rrer seeding. colon ies equal to or g rc:l rcr than 250 fLln in d i:nllerer were 
coun ted. T he data arc presented as the mean of trip licf.ltc plates. T he re was less than 10% varia tio n in the dat"' poin ts. 
/. An equa l tl umber of cell s was harvested and lysed in 1 N 1(0 1-1 . 'The hydro lysa te w",s centrifuged :\ L 1 200U.~. ,m d the O .D . at 49211111 was determ ined . Melanin contents (100%) 
in contro l FEM pMAM nco (- Dcx) represented 12. 1 fLg/ 10(' ce lls. T here wns less than IO'X, variat ion in the data po infs. 
rasR z had th e stronges t impact on the prolife ration of FEM human 
melano m a cell s. T he FEM cells were shown to express a m ore 
di ffe rentiated phenotype as de term ined by m orphological changes , 
alte red m elan.in con tent, and response to phorbol es ters [22 ,23 ] . 
M o rpho logically, rasRz clon es had elon gated dendritic processes 
an d expanded m o re sp arsely compared with contro l cells. Furth er-
m ore, of all th e ribozyme clones tested , the largest am o un t o f 
m elanin was dem o nstrated in R as-6 cells. Giuffi'c et al suggested 
th at induction of differenti atio n in m elano ma ce l.l s by ph orbol esters 
m ay lead to increased dendricity, dimini shed proliferati on capacity, 
and enhanced m elanin syn thesis [31] . O ther repo rts dem onstrated 
the loss of pigm entatio n in v -J-I- ras transfo rmed m elanocytes [7 ,32] . 
Altho ugh the precise diffe rentia tion path way in m elan om a rem ains 
unclear, o ur fin d in gs indicate that th e rasR z can induce a diffe ren-
tiated phenotypic chan ge in FEM m elano m a cells. O ur results 
indicate th at suppression o f activa ted ras gen es leads to profound 
effects o n cell g rowth and di ffe rentiatio n of m elano m a cell s i ll IIi /ro. 
R ecent reports usin g anti-sense RNA to d ownregulate the 
nuclear proto-on cogen es c-fos and C-I/I )'C showed that the m alignant 
phen otype was partiaUy reversed in activ ated ras-transformed NIH 
3T3 cell s [29,33]. T hese o bservatio ns sugges ted that nucl ear p ro to-
oncogenes were in volved in the main tenance of th e ac tiva ted 
ras-transfonned phen o type in murine fibroblas ts. EJ human bladder 
cells comm onl y used in experimental m o dels have a ho mozygous 
mutatio n pa ttern o f H - ras [3 4]. Assumin g that RNA m odula to rs 
such as the rasR z co uld completely di srupt the ac ti va ted ras 
transcrip ts, cells ha vin g n o n ormal ras counterpart w ill be greatly 
affected w ith an imlbili ty to m aintain th e steady- state expression 
level of oncogenes located downstream of the ras-related pathway. 
W e previo usly reported that a ribozyme aga ins t activated ras 
tra nscrip ts could almost compl etely reverse the malignant phen o-
typ e o f EJ ras- transform ed NIH 3T3 cells and EJ bladder ca rcinom a 
itself [16,35]. In this regard , FEM human m elan o m a cells, having 
the heterozygous patte rn o f H-ras mutation , provide an in triguing 
comparison of th e e ffi cacy of ribozym es ta rgeting activated ras and 
nucl ea r proto-oncogenes. 
T h e control of gen e expression by c-fos is b e lieved to playa 
critica l ro le in th e cellul ar response to growth or di ffe rentiation 
factors. R ecent observa tions h ave sugges ted that alterations in 
n orm al c-fos expressio n can lead to oncogenesis [36] . Yamanishi e/ 
al reported that c-fos mRNA levels were in creased in rapidly 
pro li fe rating neon atal m elanocytes and in human m elan omas [37]. 
[n con trast, o th er repo rts indicated that c-fos expression was not 
in creased in murine melano m a cell lin es [38]. Even thou gh the role 
of c-fos in m elanoma rem ains controversial , the presen t study 
indicates tha t FEM cells transfec ted with the fos lu had a longer 
doubling time than con tro l FEM cells, yet still grew more rapidly 
than rasR z clon es. FosRz clon es also sho w ed enh an ced m elanin 
synthesis, tho ugh this enh an cement was the least of the three 
ribozymes. M o rphological alte rations in fosR z clon es revealed a 
spindle-like shape and t ightly packed colon y fo rmation . T hese 
fi ndings on cell growth and m elanin content may indica te that 
di rec t down- m odulation of c-fos express io n by the ribozym e may 
be in volved m o re in regul ation of pro li fe ration rath er than of 
d iffe ren tiatio n in FEM human melano m a ce lls. 
c-I/I)'c, ano ther nuclear pro to-oncogen e examined in this study, 
has been th ought to participa te in the response of cultured cells co 
di ffe rentiation agents and mi togenic stimuli . T he introduction of 
high levels of exogeno us C-III)'C into cell lin es , e ither by inj ection of 
pur ified prote in o r in trodu ction of C-I/I)'C o r V-I/I)'C expression 
vectors, results in th e induction o f g rowth facto r independent DNA 
synthesis and in som e cases induces stable cell proli fe ration [39]. 
Furthermo re, C-I/I)'c anti-sense o ligonuleotides inhibit the pro li fer-
ation of the prom yelocytic cell lin e HL-60 [40] and mitogen-
stimulated peripheral T cells [4 1]. In melano m a, 50% of m elanoma 
cell lines exh.ibit c-I/I)1c overexpression , w hi ch m ay be re lated co 
metastatic capacity [42,43] . T hese alte ratio ns have been m ostl )' 
o bserved in high-passage cell lines , however , sugges ting the possi-
bili ty of cul ture arti facts [44]. In om study, the l/I)1cR z could 
decrease the g rowth rate, but its e ffi cacy w as lo w est am ong the 
three ribozym es. In gen eral, C-I/IYc expression is decreased in a 
number o f ce ll Jjnes fo ll owing exposure to diffe rentiation stimuli, 
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Figure 3. Morphology ofFEM ribozyme transfeeted cells. A) FEMpMAMII1·O. 8) FEMrnsRz clone 6. C) FEMji).du clone 3. 0) FEM I/Iyrlu clonc 
10. These cell s were grown for 4 d in the presI.!ncc of n.s p.M De" in monolayer culture. Magll!firnti(II/, X l 00. 
suggesting that 11I)'e downl"egulation may be important for terminal 
differentiation [45]. In fact, difFerentiated melanoma ceUs treated 
with bromodeoxyuridine reveal decreased C-III)'C mRNA levels and 
exhibit a flat morphology [46] . In o ur stud ies, the lII)'cRz clones 
were shown to produce larger amounts of melanin than the JosRz 
clone. In addition , the lIIycRz clones exhibi ted increased surface 
area , with an expanded, reticular pattern of colony formation. 
T hese alterations may be interpreted as a sign of accelerated 
differentiation. 
In rasRz transfectants, decreased H-rns gene expression was 
associated with reduced levels of c-Jos and C-III)'C mRNA. This is 
consistent with a previous report suggesting that rns-transformed 
fi broblasts overexpressed c-Jos and C- III )'C [45,47]. We have also 
demonstrated the decreased express ion ofbFGlo in the .Ras-6 clone, 
w ith the longest doubling time . T his growth factor may contribute 
to tumor progression of human melanoma as evidenced by the 
suppression of m elan oma cell growth after inhibition of bFGF 
activity by antisense o ligonucleotides [48] . Moreover, the human 
bFGF gene contains a potential AP-l binding site within the core 
promoter region [49], suggesting its regulation by the Fos/Jun 
heterodimer. 
In conclusion, these observations indica te that targeting a gene 
upstream in the signal transduction pathway (such as H-ms) was 
most effective in the reversion of the malignant phenotype of 
human me lanoma cells. Moreover, they suggest that the efFect 
of the msRz may be partly mediated through the downregulation of 
genes in the ms-related pathway, including possibl y c-Jos and C-III)1C. 
In terms of clinical application, even though ribozym e strategies are 
sti ll in theif in cipient stages, our results suggest the possi bility that 
anti-oncogene ribozymes could play a role as suppressors of the 
neoplastic phenotype. 
Itfl e tlulIlk }\4.,-. C(Jm/ Po/c/wII'Iorpl'qJflriltg fh e IIuIIIIlscripf, This work IIIas sIIppmied 
by gralllS ) ;'o", tile Na tiollal 111stilllles ~r H ealril (CA506 18) all d Celie S IIears, Lrd., 
AlIslralia. 
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